Mario Ballarin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mario Ballarin has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Maria Angela Mazzi
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
3 shared publications - Claudia Goss
University of Verona
2 shared publications Federica Chiodera
Department of Public Health and Community Medicine, Section of Clinical Psychology, University of Verona, Italy
2 shared publications- Irene Bighelli
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich, Germany; DZPG (German Center for Mental Health), Partner Site Munich/Augsburg, Munich, Germany
2 shared publications A. Bottacini
Department of Public Health and Community Medicine, Section of Clinical Psychology, University of Verona, Policlinico G.B. Rossi, Piazzale L.A. Scuro 10, 37134 Verona, Italy
1 shared publicationA. Molino
O.U. of Oncology d.O., Ospedale Civile Maggiore, Hospital Trust of Verona, Italy
1 shared publication
Latest Publications
- Open Access
- 23 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 2065
Exploration of Early-Treatment-Associated Changes in Metabolic and Inflammatory Biomarkers in First-Episode Psychosis in Italian Patients
Studies conducted in first-episode psychosis (FEP) patients have shown alterations in inflammation and metabolism. Our objective was to investigate potential treatment-related effects on these systems in Italian FEP patients undergoing either an experimental treatment consisting of a multi-element psychosocial intervention (EXP), including cognitive–behavioural therapy, or treatment as usual (TAU). A total of 191 FEP patients with first contact between April 2010 and March 2011 were clinically assessed at baseline and after 9 months of treatment, and the serum levels of 19 analytes were determined through single or multiplex enzyme-linked immunosorbent assays (ELISAs). A significant increase was observed in leptin levels and a significant decrease in Glucagon-Like Peptide-1 (GLP-1) levels during the treatment (time effect, p < 0.001 for both), with no significant interaction between time and treatment type. Although ghrelin levels changed significantly over time in the whole cohort (p = 0.008), a significant decrease was observed only in the EXP group (post hoc test: p = 0.001). None of the biomarkers measured at baseline showed a predictive effect on treatment efficacy, and no significant associations were identified between changes in clinical scores and changes in biomarker levels. These results suggest that early-phase psychosis treatments are associated with possible effects on metabolic regulation.
- 23 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 2065
Open AccessExploration of Early-Treatment-Associated Changes in Metabolic and Inflammatory Biomarkers in First-Episode Psychosis in Italian Patients
Studies conducted in first-episode psychosis (FEP) patients have shown alterations in inflammation and metabolism. Our objective was to investigate potential treatment-related effects on these systems in Italian FEP patients undergoing either an experimental treatment consisting of a multi-element psychosocial intervention (EXP), including cognitive–behavioural therapy, or treatment as usual (TAU). A total of 191 FEP patients with first contact between April 2010 and March 2011 were clinically assessed at baseline and after 9 months of treatment, and the serum levels of 19 analytes were determined through single or multiplex enzyme-linked immunosorbent assays (ELISAs). A significant increase was observed in leptin levels and a significant decrease in Glucagon-Like Peptide-1 (GLP-1) levels during the treatment (time effect, p < 0.001 for both), with no significant interaction between time and treatment type. Although ghrelin levels changed significantly over time in the whole cohort (p = 0.008), a significant decrease was observed only in the EXP group (post hoc test: p = 0.001). None of the biomarkers measured at baseline showed a predictive effect on treatment efficacy, and no significant associations were identified between changes in clinical scores and changes in biomarker levels. These results suggest that early-phase psychosis treatments are associated with possible effects on metabolic regulation.
- 17 March 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (5) , 451-457
Information needs of female Italian breast cancer patients during their first oncological consultation
- 17 March 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (5) , 451-457
Information needs of female Italian breast cancer patients during their first oncological consultation
- 1 June 2014
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 18 (3) , 299-304
Asking questions during breast cancer consultations: Does being alone or being accompanied make a difference?
- 1 June 2014
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 18 (3) , 299-304
Asking questions during breast cancer consultations: Does being alone or being accompanied make a difference?
- Open Access
INvolvement of breast CAncer patients during oncological consultations: a multicentre randomised controlled trial—the INCA study protocol
Introduction Studies on patient involvement show that physicians make few attempts to involve their patients who ask few questions if not facilitated. On the other hand, the patients who participate in the decision-making process show greater treatment adherence and have better health outcomes. Different methods to encourage the active participation during oncological consultation have been described; however, similar studies in Italy are lacking. The aims of the present study are to (1) assess the effects of a preconsultation intervention to increase the involvement of breast cancer patients during the consultation, and (2) explore the role of the attending companions in the information exchange during consultation. Methods and analysis All female patients with breast cancer who attend the Oncology Out-patient Services for the first time will provide an informed consent to participate in the study. They are randomly assigned to the intervention or to the control group. The intervention consists of the presentation of a list of relevant illness-related questions, called a question prompt sheet. The primary outcome measure of the efficacy of the intervention is the number of questions asked by patients during the consultation. Secondary outcomes are the involvement of the patient by the oncologist; the patient's perceived achievement of her information needs; the patient's satisfaction and ability to cope; the quality of the doctor–patient relationship in terms of patient-centeredness; and the number of questions asked by the patient's companions and their involvement during the consultation. All outcome measures are supposed to significantly increase in the intervention group. Ethics and dissemination The study was approved by the local Ethics Committee of the Hospital Trust of Verona. Study findings will be disseminated through peer-reviewed publications and conference presentations. Trial registration ClinicalTrials.gov identifier: NCT01510964
Open AccessINvolvement of breast CAncer patients during oncological consultations: a multicentre randomised controlled trial—the INCA study protocol
Introduction Studies on patient involvement show that physicians make few attempts to involve their patients who ask few questions if not facilitated. On the other hand, the patients who participate in the decision-making process show greater treatment adherence and have better health outcomes. Different methods to encourage the active participation during oncological consultation have been described; however, similar studies in Italy are lacking. The aims of the present study are to (1) assess the effects of a preconsultation intervention to increase the involvement of breast cancer patients during the consultation, and (2) explore the role of the attending companions in the information exchange during consultation. Methods and analysis All female patients with breast cancer who attend the Oncology Out-patient Services for the first time will provide an informed consent to participate in the study. They are randomly assigned to the intervention or to the control group. The intervention consists of the presentation of a list of relevant illness-related questions, called a question prompt sheet. The primary outcome measure of the efficacy of the intervention is the number of questions asked by patients during the consultation. Secondary outcomes are the involvement of the patient by the oncologist; the patient's perceived achievement of her information needs; the patient's satisfaction and ability to cope; the quality of the doctor–patient relationship in terms of patient-centeredness; and the number of questions asked by the patient's companions and their involvement during the consultation. All outcome measures are supposed to significantly increase in the intervention group. Ethics and dissemination The study was approved by the local Ethics Committee of the Hospital Trust of Verona. Study findings will be disseminated through peer-reviewed publications and conference presentations. Trial registration ClinicalTrials.gov identifier: NCT01510964